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Coronary aneurysms are rare after conventional angioplasty and 
have not been reported after coronary stenting. Coronary artery 
stent sites were examined by follow-up angiography at a median of 
4 months in 29 patients who received the Cook stent (Gianturco-
Roubin) for acute coronary closure. Nineteen patients were 
treated with glucocorticoids administered intravenously or orally, 
or both, with or without colchicine and results were compared 
with those in 10 patients who were treated with neither agent. 
Standard therapy for all patients included routine administration 
of aspirin and heparin before and warfarin sodium (Coumadin) 
and aspirin after stent placement. Most patients also received 
dipyridamole and lovastatin during the follow-up period. Compli-
ance with medications was confirmed by telephone conversation 
with each patient. 
Coronary stents represent an important advance in the 
management of abrupt coronary closure due to severe dis-
section after balloon angioplasty (1-5). Intimal proliferation 
after stent placement has been noted histologically in animal 
models (6,7) and in clinical applications. In some cases (8), 
this proliferation progresses to cause a clinically significant 
reduction in lumen size. 
Although intracoronary stents are capable of maintaining 
a widely patent vessel immediately after coronary angio-
plasty, there has been concern about thrombosis of the 
stented segment. Early thrombosis was noted in 18% to 24% 
of stent placements in two separate models (9, 1 0). This 
experience led the investigators to use a vigorous anticoag-
ulant and antiplatelet regimen that seems to have reduced 
this problem significantly (l ,2,9). The problems of significant 
intimal hyperplasia (proliferation) or restenosis remained. 
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Six (32%) of the 19 stented arteries showed evidence of 
coronary artery aneurysm, defined as expansion of the lumen 
outside the margins of the stent. None of the patients in the control 
group (who did not receive steroids or colchicine) developed 
aneurysm. This pattern of altered vascular healing in stented 
coronary segments appears to be due to the addition of multiple 
anti-inflammatory drugs rather than to stent presence alone. This 
observation demonstrates the possibility of medical impairment of 
normal vascular remodeling after acute injury and stent place-
ment, which may be of benefit in designing future trials on 
restenosis. 
(JAm Coli Cardio/1991;18:1524-8) 
Therefore, in addition to these medications, the patients 
described here also received glucocorticoids and colchicine 
in an attempt to retard an aggressive neointimal regrowth 
seen in some of these patients. 
Hydrocortisone has been shown experimentally to be 
additive with heparin in inhibiting vascular smooth muscle 
cell proliferation after balloon injury (11). In another exper-
imental model colchicine inhibited restenosis; this effect was 
thought to be due to the drug's antimitotic properties and to 
inhibition of cellular motility (12). In addition, lovastatin has 
been suggested to be beneficial in reducing restenosis after 
balloon angioplasty (13). Therefore, hydrocortisone, pred-
nisone, colchicine and lovastatin were added to the an-
tithrombotic regimen in an attempt to moderate intimal 
proliferation within the stent. We report paradoxic arterial 
dilation and frank aneurysm formation within stented arter-
ies after specific drug therapy, occurring within a few 
months of stent placement. 
Methods 
Patients and drug treatment. Nineteen patients who re-
ceived the Cook, Inc. (Gianturco-Roubin) stent for acute or 
threatened acute coronary closure were given 50 mg oral 
hydrocortisone or 40 mg oral prednisone daily' tapered over 
2 weeks, or intravenous glucocorticoids (100 to 200 mg 
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Table 1. Description and Size of Coronary Aneurysm in Six Patients 
Arterial Arterial Aneurysm 
Diameter* Stent Diameter* Diameter*+ at 
Pt Age (yr)/ Before Stenting Sizet After Stenting Follow-Up Aneurysm Associated 
No. Gender Indication Site (mm) (mm) (mm) (mm) Type Restenosis 
I 56/M Coronary dissection Proximal RCA 4.4 4.7 5.49 Saccular No 
2 42/M Intimal tear and Mid-LAD 3.22 3.28 5.75 Saccular Yes 
occlusion 
53/M Intimal tear and Proximal RCA 2.95 3.5 3.48 4.63 Saccular Yes 
occlusion 
4 62/F Intimal tear and LCx 2.58 3.14 4.81 Saccular Yes 
occlusion 
5 42/F Intimal tear and Proximal LAD 2.52 2.83 4.75 Fusiform No 
occlusion 
6 42/M Intimal tear Mid-RCA 4.19 4 3.85 7.21 Fusiform No 
*Diameters of coronary arteries and aneurysms were measured by digital electronic calipers (Sandhill). tSize reported by the manufacturer; the stents are 
delivered by way of a balloon 0.5 mm larger than the stent. :\:Measured at stent site. F = female; LAD = left anterior descending coronary artery; LCx = left 
circumflex coronary artery; M = male; Pt = patient; RCA= right coronary artery. 
Figure 1. Patient 3. Right coronary angiograms. A, Acute coronary 
closure (arrow); B, Vessel appearance (arrow) immediately after place-
ment of a 3.5-mm Cook stent. C, Saccular aneurysm (arrow) noted at 
3-month follow-up. Brackets in B and C indicate stented segments. 
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Solu-Cortef or Solu-Medrol) at the time of stent implanta-
tion, in an effort to reduce restenosis in the stented coronary 
artery. In addition, 15 patients received oral colchicine 
(1.2 mg daily). Ten randomly selected control patients did 
not receive any steroidal agent or colchicine after stenting. 
Heparin (10,000 to 20,000 U) was given along with dextran 
40 solution (100 ml/h over 5 h) intravenously during the 
angioplasty and stenting procedure performed in the cardiac 
catheterization laboratory. Aspirin was routinely given be-
fore the procedure. Daily administration of the following 
drugs was started immediately after the procedure: warfarin 
(to maintain prothrombin time 1.5 to 2 times control), aspirin 
(80 to 325 mg), dipyridamole (100 to 225 mg) and lovastatin 
(20 to 40 mg). In addition, the heparin infusion was contin-
ued until a therapeutic prothrombin time was achieved with 
warfarin. These drugs were considered to be relatively safe 
and tolerable and none of the patients reported discontinuing 
the medications due to adverse drug effects. 
Stent placement. The method of insertion of the Giant-
urco-Roubin stent has previously been described for this 
indication and was not altered in this group of patients (2). 
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Figure 2. Patient 5. Left anterior descending coronary angiogram. A, 
Acute vessel closure (arrow). B, Vessel appearance (arrow) immedi-
ately after placement of a 3-mm Cook stent. C, Fusiform aneurysm 
(arrow) noted at 3-month follow-up. Brackets in 8 and C indicate 
stented segment. 
Follow-up. Follow-up coronary angiograms were re-
viewed by two experienced angiographers who did not know 
the treatment protocol. Coronary aneurysm was defined as 
the presence of luminal dimensions beyond the stent borders 
and each aneurysm was further classified as saccular or 
fusiform. 
Results 
Clinical and angiographic characteristics (Table 1). Four 
month (median) angiographic follow-up was obtained in 
all 29 patients. Six (32%) of the 19 patients treated with 
glucocorticoids with or without colchicine developed a cor-
onary aneurysm in the stented segment. Three of these six 
arterial sites also had areas of >50% reduction in luminal 
diameter in the stented segment. Representative examples 
from this patient group are shown in Figures l to 3. No 
patient has yet experienced a clinical event attributable to 
the aneurysm. 
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Discussion 
Coronary aneurysms after angioplasty. Aneurysm forma-
tion is rare after coronary angioplasty (14) and has not been 
reported in stented coronary arteries (Marco J, personal 
communication, March 1991). We are not aware of any 
reports of increased coronary aneurysm formation with the 
use of warfarin, aspirin, dipyridamole or lovastatin. Simi-
larly, reports of clinical trials (15-17), including trials of 
glucocorticoids for the prevention of restenosis after coro-
nary angioplasty, have not described coronary aneurysm 
formation. In addition, failure of any of the control patients 
in this study to develop an aneurysm suggests that stent 
design or placement is unlikely to be contributing to this 
process. 
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Figure 3. Patient 1. Right coronary angiogram. A, High grade 
stenosis (arrow) before balloon angioplasty. B, Severe coronary 
dissection (arrow) after angioplasty. C, Vessel appearance (arrow) 
immediately after placement of a 3-mm Cook stent. D, Saccular 
aneurysm (arrow) noted at 3-month follow-up. Brackets in C and D 
indicate stented segments. 
Vascular healing and pharmacologic inhibition. Adminis-
tration of hydrocortisone with prednisone and colchicine can 
influence healing after tissue necrosis. Hydrocortisone has 
been shown (18) to significantly decrease vascular smooth 
muscle cell proliferation in vitro by modulating transmem-
brane signals induced by growth factors. Colchicine inhibits 
inflammation and fibrosis by binding to microtubule protein 
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and inducing metaphase arrest in fibroblasts as well as by 
decreasing collagen turnover and increasing collagenase 
activity (12,19). Cellular proliferation (of smooth muscle 
cells and myofibroblasts) and synthesis of matrix collagen 
are the hallmarks of intimal hyperplasia, which is the his-
tologic equivalent of remodeling and restenosis. 
Lack of aneurysm formation in other stents. Medial atro-
phy around the relatively rigid Palmaz-Schatz stent has been 
demonstrated when the vascular wall is protected from 
repetitive, dynamic bending of the site induced by the 
cardiac cycle (9,20). Whether this happens to some degree in 
patients with a Cook stent with the flexing coil design has not 
been established. Because human histologic studies are not 
available, one can only speculate as to whether these 
changes are exacerbated by the addition of hydrocortisone 
and colchicine to anticoagulant and antiplatelet agents, re-
sulting in altered coronary healing with wall thinning and 
aneurysm formation. The deep medial dissection seen in this 
study secondary to balloon injury might also be expected to 
influence late aneurysm formation. However, such changes 
have not been observed in patients undergoing stent place-
ment in this series who were not treated with these drugs. 
Conclusions. The clinical observations reported here 
were not part of a structured, controlled clinical trial. 
However, the findings in this limited patient group suggest 
that pharmacologic strategies for preventing restenosis are 
not totally benign and that attempts to reduce restenosis may 
be associated with new problems of abnormal wall healing 
and with an unknown potential for complications in the 
future. The demonstration that vascular healing can be 
impaired will be an important consideration in future efforts 
to prevent restenosis. 
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